Nozomi Matsuura

Dr. Nozomi Matsuura


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
NMNozomi Matsuura
Nozomi Matsuura
MKMasaya Kanayama
Masaya Kanayama
YWYuta Watanabe
Yuta Watanabe
HYHirokazu Yamada
Hirokazu Yamada
LLLoukia Lili
Loukia Lili
ATAkira Torii
Akira Torii
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients. Methods: Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (−38.0 [95% confidence interval (CI): −53.6, −22.4]; p < 0.001), in patients with IBS-D (−44.5 [95% CI: −70.6, −18.5]; p = 0.004) and IBS-C (−51.2 [95% CI: −79.4, −22.9]; p = 0.002), but not in those with IBS-M (−20.0 [95% CI: −48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention. Conclusions: In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.